Ready to upload
Adverse Occurrence type:
Time to detection:
Alerting signals, symptoms, evidence of occurrence:
Demonstration of imputability or root cause:
Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998 Mar 15;91(6):1833-44
A new review is necessary - record unpublished (EP) 5/20/18: This review article deals wieth PTLD, myelodysplastic syndromes, leukemias, and solid tumors that might arise as a result of various recipient risk factors and therapeutic regimens, and does not actually deal with the subject of donor transmitted malignancies (even though some of these tumors like leukemias ultimately arise in donor cells). Therefore I would recommend that we not include it in our listing. Mike N. 5/21/18 Kerstin: perfect summary by Mike. I would like to suggest keeping this record to be comprehensive. It describes no new cases but makes reference to some and gives some nice Information and points of view to better understand the topic. 6/1/18: I have no problem with that. I moved the discussion from the imputability textbox to the expert comments for publication textbox.
Expert comments for publication:
Review article about hematopoietic and solid organ malignancies after stem cell transplantation (PTLD, lymphoma, MDS, acute leukemia and solid tumors after allogenic and autologous stem cell transplantation). Regarding donor-derived leukemia: some reported cases in the literature describe secondary leukemia developing in donor cells in the recipient but not in the donor itself, the donors remained healthy. Diagnosis confirmed between 6 months and more than 3 years after stem cell transplantation. Several possible mechanisms of the development of secondary leukemia in previously healthy transplanted donor cells are discussed but remain hypotheses. Regarding solid tumors after allogenic transplantation: only de novo malignancies and their risk factors in the setting of stem cell transplantation are discussed here (e.g. total body irradiation, Fanconi anemia, GVHD). No new or unpublished donor-derived or -transmitted tumors.